Modulating bone marrow hematopoietic lineage potential to prevent bone metastasis in breast cancer by Ubellacker, J.M. et al.
This is a repository copy of Modulating bone marrow hematopoietic lineage potential to 
prevent bone metastasis in breast cancer.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/135484/
Version: Accepted Version
Article:
Ubellacker, J.M., Baryawno, N., Severe, N. et al. (13 more authors) (2018) Modulating 
bone marrow hematopoietic lineage potential to prevent bone metastasis in breast cancer. 
Cancer Research . ISSN 0008-5472 
https://doi.org/10.1158/0008-5472.CAN-18-0548
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless 
indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by 
national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of 
the full text version. This is indicated by the licence information on the White Rose Research Online record 
for the item. 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
Modulating bone marrow hematopoietic lineage potential to prevent bone 
metastasis in breast cancer 
 
Jessalyn M. Ubellacker1,2, Ninib Baryawno3,4,5, Nicolas Severe3,4,5, Molly J. DeCristo1,2, 
Jaclyn Sceneay1,2, John N. Hutchinson6, Marie-Therese Haider7, Catherine S. Rhee3,4,5, 
Yuanbo Qin1,2, Walter M. Gregory8, Ana C. Garrido-Castro9, Ingunn Holen7, Janet E. 
Brown7, Robert E. Coleman7, David T. Scadden3,4,5,10, Sandra S. McAllister1,2,5,10  
 
1
Hematology Division, Brigham & Women’s Hospital, Boston, Massachusetts, 02115, USA.  
2
Department of Medicine, Harvard Medical School, Boston, Massachusetts, 02115, USA. 
3
Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, 
Massachusetts, 02138, USA.  
4
Center for Regenerative Medicine and the Cancer Center, Massachusetts General 
Hospital, Boston, Massachusetts, 02114, USA. 
5
Harvard Stem Cell Institute, Cambridge, Massachusetts, 02138, USA.  
6
Department of Biostatistics, Harvard T.H. Chan, School of Public Health, Boston, 
Massachusetts, 02115, USA.  
7
Academic Unit of Clinical Oncology, Department of Oncology & Metabolism, Weston Park 
Hospital, University of Sheffield, Sheffield, UK, S10.  
8
Clinical Trials Research Unit, University of Leeds, Leeds, UK, LS2 9NL. 
9
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, 
02115, USA.  
10
Broad Institute of Harvard and MIT, Cambridge, Massachusetts, 02142, USA. 
 
Corresponding author: Sandra S. McAllister, (+01) 617-525-4929, 
smcallister1@bwh.harvard.edu 
 
Running title: Modulating bone marrow to prevent breast cancer metastasis 
 
Keywords: breast cancer, bone metastasis, hematopoiesis, bone marrow, myeloid cells, 
myeloid/osteoclast progenitors, bisphosphonate, zoledronic acid, granulocyte-colony 
stimulating factor 
 
Conflict of interest disclosure: Robert E. Coleman has participated in a 
consultant/advisory board relationship with Amgen, has leadership affiliation with prIME 
Oncology, and has ownership interests in Inbiomotion. Janet E. Brown has participated in a 
consultant/advisory board relationship with and has received honoraria from Amgen and 
Novartis. All other authors have declared that no conflict of interest exists. 
 
Financial Support:  This work was supported by funds from NIH T32 GM007226, NIH NCI 
F31CA195797 for J. Ubellacker; NIH R01DK107784, NIH NCI U54CA163191 to D. 
Scadden; U.S. Department of Defense Era of Hope W81XWH-14-1-0191, NIH NCI RO1 
CA166284 with PECASE supplemental to S. McAllister. 
 
Word count: 6,994 
Number of figures: 7 
 
 
Research. 
on September 7, 2018. © 2018 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on July 31, 2018; DOI: 10.1158/0008-5472.CAN-18-0548 
1 
 
ABSTRACT  
The presence of disseminated tumor cells in breast cancer patient bone marrow 
aspirates predicts decreased recurrence-free survival. Although it is appreciated that 
physiological, pathological, and therapeutic conditions impact hematopoiesis, it remains 
unclear if targeting hematopoiesis presents opportunities for limiting bone metastasis. 
Using pre-clinical breast cancer models, we discovered that marrow from mice treated 
with the bisphosphonate zoledronic acid (ZA) are metastasis-suppressive. Specifically, 
ZA modulated hematopoietic myeloid/osteoclast progenitor cell (M/OCP) lineage 
potential to activate metastasis-suppressive activity. Granulocyte-colony stimulating 
factor (G-CSF) promoted ZA resistance by redirecting M/OCP differentiation. We 
identified M/OCP and bone marrow transcriptional programs associated with metastasis 
suppression and ZA resistance. Analysis of patient blood samples taken at random 
revealed that women with high plasma G-CSF experienced significantly worse outcome 
with adjuvant ZA than those with lower G-CSF levels. Our findings support discovery of 
therapeutic strategies to direct M/OCP lineage potential and biomarkers that stratify 
responses in patients at risk of recurrence.  
 
STATEMENT OF SIGNIFICANCE 
Bone marrow myeloid/osteoclast progenitor cell (M/OCP) lineage potential has a 
profound impact on breast cancer bone metastasis and can be modulated by G-CSF 
and bone-targeting agents.  
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INTRODUCTION 
The majority of breast cancer patients have no evidence of metastatic disease at the 
time of diagnosis, yet ~30% of patients experience recurrent breast cancer in the form 
of metastasis, of which the most prominent site is bone (1). Moreover, bone is the most 
frequent site of de novo metastasis for all breast cancer molecular subtypes (2). At 
present, little is known about what promotes tumor cell survival and outgrowth into 
incurable disease in the bone (1, 3). Disseminated tumor cells (DTCs) are frequently 
detected in bone marrow aspirates of breast cancer patients, regardless of breast 
cancer subtype and even in those who have early-stage disease, and are predictive of 
decreased recurrence-free survival (4). These and other such findings support the idea 
that DTCs find a hospitable niche in the bone marrow (4-6).  
Bone metastatic niches in which DTCs reside have been defined as 
microdomains within the bone that support tumor cell seeding and outgrowth and are 
predominantly comprised of hematopoietic cells, mesenchymal stromal cells, 
osteoblasts, osteoclasts, and/or vascular cells (5, 6). Paracrine interactions between 
DTCs and these various stromal cells disrupt bone homeostasis, which is normally 
tightly controlled, to fuel metastatic progression. For example, it is well established that 
DTCs secrete a variety of cytokines that promote osteoclast activity, which in turn, 
causes release of a variety of tumor-promoting growth factors from the bone, thus 
propagating a vicious cycle of tumor outgrowth and osteolytic bone breakdown (6).  
Although results from studies that focused on mesenchymal stromal cells, 
osteoblasts, osteoclasts, and vascular cell activity have yielded significant insights into 
cellular and molecular processes that influence DTC outgrowth and dormancy in the 
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bone (5, 6), surprisingly little is known about whether or how hematopoietic cells in the 
marrow compartment impact bone metastases. Clinical studies indicate that the 
presence of DTCs in breast cancer patient bone marrow correlates with metastatic 
relapse and poor outcome (7). In the pre-clinical setting, it is becoming increasingly 
apparent that various physiological and pathological processes as well as certain drugs 
and chemotherapies alter hematopoietic cells in the marrow in ways that impact cancer 
progression (7-10); however, it is not yet clear how DTCs are impacted when they first 
encounter such hematopoietic cells in the marrow.  
          Hematopoiesis relies on precise regulation of quiescence, proliferation, and 
differentiation of hematopoietic progenitor cells within specialized niches (11, 12). For 
example, within the osteoblastic niche, mature osteoclasts influence hematopoiesis by 
releasing bone-matrix proteins essential for hematopoietic cell maintenance (13, 14). It 
is reasonable therefore to hypothesize that modulating osteoclast (OC) activity would 
have an impact on hematopoiesis in ways that affect DTC behavior.  
We previously established that bisphosphonate treatment, which is a widely used 
osteoclast inhibitor therapy for effective treatment of osteolytic diseases, induces sub-
clinical changes in the composition of bone marrow hematopoietic progenitor 
populations (15). We reported that bone marrow cells isolated from ZA-treated animals 
suppress mammary carcinoma formation in the absence of a direct effect of ZA on 
tumor cells, indicating that the bone marrow harbors the majority of ZA’s tumor-
suppressive capacity (15). However, whether such modulation of the marrow affects 
breast cancer bone metastasis independently of the effects on mature osteoclasts in the 
endosteal niche and whether a specific subpopulation of hematopoietic cells has 
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metastasis-suppressive capacity remained undetermined. A better understanding of the 
bone marrow microenvironment and processes that influence tumor cell maintenance 
and growth in the bone should present opportunities for targeting hematopoietic cell 
populations as part of anti-cancer therapy. 
MATERIALS AND METHODS 
 
Cell lines. MDA-MB-231 B1 cells (gift from Dr. Gabri van der Pluijm), a clonal bone-
tropic human breast cancer cell line expressing luciferase, was maintained under 
selection in 1 mg/mL Gentamicin, (G418, Life Technologies, 15750060) in Dulbecco 
modified Eagle medium (DMEM) with 10% fetal bovine serum (FBS). MDA-MB-231 B2 
bone-tropic human breast cancer cells (gift from Dr. Penelope Ottewell were transfected 
with luciferase and maintained in 10% FBS in DMEM. Cells were not used beyond 
passage five post thawing. All cells tested negative for mycoplasma (Lonza Kit: LT07-
118) every 6 months (Last test: June 2017) and were validated using short tandem 
repeat (STR) profiling (Molecular Diagnostics Laboratory at Dana-Farber Cancer 
Institute, Boston, MA). 
 
Mice. Six to seven-week-old female CrTac:NCr-Foxn1nu (nude) female mice were 
purchased from Taconic Laboratories (Hudson, NY). C57BL/6J female mice were 
purchased from The Jackson Laboratory (Bar Harbor, ME). All animal procedures were 
performed in accordance with the ethics and regulations of Brigham & Women’s 
Hospital Institutional Animal Care and Use Committee (protocol approval 
2017N000056), Boston Children’s Hospital Institutional Animal Care and Use 
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Committee (protocol approval 12-11-2308R), and Massachusetts General Hospital 
(protocol approval 2017N000023). 
 
Drug administration. Zoledronic acid (ZA) [1-hydroxy-2-(1H-imidazole-1-yl)ethylidene-
bisphosphonic acid] (Novartis Pharmaceuticals, Cambridge, MA) was dissolved in 1X 
Hank’s Balanced Buffer Solution (Gibco) and stored at 4°C until use. ZA was 
administered to mice at a dose of 100 µg/kg (i.p.). Recombinant human granulocyte 
colony stimulating factor (G-CSF) (carrier-free, Biolegend #578604) was administered to 
nude mice each day for 3 days at a dose of 50 µg/kg (i.p.) beginning one day after 
administration of ZA, and C57BL/6 mice each day for 3 days at a dose of 50 µg/kg (i.p.) 
beginning 2 days after administration of ZA. For G-CSF depletion experiments, nude 
mice were treated with 100 µg/kg (i.p.) G-CSF antibody (R&D Systems, MAB414100) or 
the 100 µg/kg (i.p.) isotype control IgG (R&D Systems, MAB005) six hours prior to 
intracardiac injection of tumor cells. 
 
Blood and plasma. At experimental end points, blood was collected by intracardiac 
puncture with a 27-gauge needle into ethylenediaminetetraacetic acid (EDTA) 
Microtainer tubes (BD Pharmingen). Complete blood counts were obtained using a 
HEMAVET® hematology analyzer (Drew Scientific). Plasma was prepared by 
centrifugation of whole blood at 1.5 g x 1000 for 8 minutes at 4 °C. 
 
Experimental bone metastasis. Mice were anesthetized with isoflurane, and 1x105 
luciferase-tagged bone-tropic cell lines (B1, B2, B1-G, B2-shG) were suspended in 100 
µL of PBS and injected into the left cardiac ventricle. Tumor growth was monitored by 
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bioluminescence imaging, and by Vybrant® CM-Dil cell-labeling solution by florescence 
imaging (Life Technologies, V22888).  For intratibial injections, mice were anesthetized 
with isoflurane and 5x104 cells in 10 µL of PBS were injected directly into both tibiae. 
Tumor growth was monitored by bioluminescence imaging. In indicated experiments, 
mice were treated with 100 µg/kg of ZA or equivalent volume of vehicle control 72 hours 
prior to injection of tumor cells. 
 
Bone marrow cell preparations. Femora and tibiae were dissected free into 2% FBS 
in PBS and centrifuged at 6.0-7.0 g x1000 for 4 minutes at 4 °C to collect whole BMCs 
(WBM). Cells were then incubated with red blood cell (RBC) lysis solution (BioLegend, 
420301) for 5 minutes on ice, washed once with 2% FBS in PBS, re-suspended in 
0.5 mL of sterile BMC buffer, and passed through a 5-mL polystyrene round-bottom 
tube with a cell-strainer cap (Corning, 352235).  
 
Flow cytometry and FACS. BMCs were prepared for flow cytometry by suspension in 
sterile PBS containing 2% FBS. Cells were labeled with appropriate antibodies for 30 
minutes at 4°C. Gating was used to exclude debris, cell clumps, and dead cells (using 
7-aminoactinomycin D; 7-AAD Viability Staining Solution (BioLegend, 420404). 
Myeloid/osteoclast progenitor cell (M/OCP) populations were defined as Lineage- 
CD115+.  Antibody panel includes: Pacific BlueTM anti-mouse Lineage Cocktail 
(BioLegend, 133310: CD3-, Ly-6G/Ly6-C-, Cd11b-, CD45R-, TER119-) and Alexa 
Fluor® 488 anti-mouse CD115 (CSF-1R; BioLegend, 135511). Cells were acquired on a 
Canto II or a FACSAria IIu/FACSDiva (BD Biosciences). At the endpoint of the 
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osteoclast differentiation assays, macrophages were defined as 
MHCII+/F4/80+/Cd11b+ (MHCII: APC-Cy7 (BioLegend 107627), F4/80: PE-Cy-7 
(BioLegend 123113), Cd11b:Alexa Fluor-488 (BioLegend 101205)) and dendritic cells 
were defined as MHCII+/Cd11b+/Cd11c+ (MHCII: APC-Cy7 (BioLegend 107627), 
Cd11c: PE (BioLegend 117307), Cd11b:Alexa Fluor-488 (BioLegend 101205)). 
Analyses were performed using FlowJo software (FlowJo, LLC). CountBright TM 
Absolute Counting Beads (Life Technologies, C36950) were used to quantify absolute 
cell numbers. For cell sorting of the M/OCP populations and for isolation of Lin- and 
Lin+ populations, the Murine Direct Lineage Cell Depletion Kit (Miltenyi Biotec Inc., 130-
110-470) was used to enrich for Lin- populations, which was confirmed by flow 
cytometry for the markers in the lineage cocktail. 
 
Bone marrow tumor support functional assay. Donor mice were treated via i.p. 
injection with vehicle (1X HBBS) or ZA (100ug/kg) and sacrificed 3 days (nude mice) or 
5 days (C57BL/6 mice) following treatment. BMCs were harvested as described above. 
For whole bone marrow (WBM) assays, 750,000 donor BMCs were mixed with 250,000 
of the appropriate tumor cells in 100uL DMEM with 10% Basement membrane matrix, 
CorningTM Matrigel Growth Factor Reduced (Low Growth) (Westnet Inc., 354230) 
immediately prior to injection. To test the tumor support function of various FACS-
isolated marrow subpopulations, 250,000 tumor cells were mixed with either 250,000 
Lin- BMCs, 750,000 Lin+ BMCs, or 100,000 M/OCPs. Admixtures were injected 
subcutaneously into host nude mice. During the 14-day time courses, no graft versus 
host disease was observed for nude mice receiving C57BL/6 donor marrow. Each donor 
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BMC sample was distributed into a minimum of 3 host nude mice. Tumor growth was 
monitored by bioluminescent imaging. 
 
Osteoclast differentiation assay. Bone marrow cells were prepared as previously 
described, and 1,000 WBM cells or 250 M/OCP cells were plated in 24-well plates with 
15% FBS in αMEM with 10 ng/mL of Recombinant M-CSF (R&D Systems, 416ML010). 
After 3 days, recombinant RANKL (5 ng/mL R&D Systems, 462TEC010CF) or vehicle 
control were added to the assay. At the 5-day end point, Tartrate Resistant Acid 
Phosphatase, Leukocyte (TRAP) Kit (Sigma Aldrich, 387A) was used and TRAP-
positive osteoclasts were counted and flow cytometry was performed to quantify the 
numbers of macrophages and dendritic cells in the resultant cultures. To test phagocytic 
function of the resulting cultures, tumor cells were stained with Vibrant CM-Dil (Life 
Technologies) at a concentration of 5 µL CM-Dil solution per 1 million cells/mL for 5 
minutes at 37 degrees. Cells were washed twice with PBS, and then 1,000 tumor cells 
were added into the wells at the endpoint of the osteoclast differentiation assay. After 
two hours, wells were washed with PBS and prepared for flow cytometry. Cells within 
the macrophage gate that were CM-Dil+ were reported as a percentage of the total 
macrophage population. 
 
Patient plasma samples. Breast cancer patient plasma samples (n=392) were 
obtained from the AZURE clinical trial sample database (ISRCTN79831382, University 
of Sheffield) (16). The AZURE study was performed in accordance with the Declaration 
of Helsinki, and was performed after approval by an institutional review board (IRB) 
(West Midlands Research Ethics Committee). Patients were randomized to either 
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standard adjuvant therapy alone (Ctl) or with zoledronic acid (ZA) (Novartis 
Pharmaceuticals, Summit, New Jersey, USA) and written informed consent was 
received from all patients prior to inclusion in the study. To reduce possible imbalances 
in tumor and treatment characteristics, a minimization process was used that took into 
account the number of involved axillary lymph nodes, clinical tumor stage, estrogen 
receptor status, type and timing of systemic therapy, menopausal status, statin use and 
treating center. Eligible patients were randomized to receive (neo) adjuvant 
chemotherapy and/or endocrine therapy +/- ZA 4mg iv every 3-4 weeks for 6 doses, 
then 3 monthly x8 and 6 monthly x5 to complete 5 years of treatment. Secondary 
prophylaxis with G-CSF to prevent neutropenic sepsis or treatment delays due to 
neutropenia was allowed but primary G-CSF prophylaxis was not used. Both the use of 
adjuvant systemic treatments and loco-regional radiotherapy were given in accordance 
with standard protocols at each participating institution. The date of recurrence was 
defined as the date on which relapse was first suspected. Subjects were followed up on 
an annual basis after completion of the 5-year treatment phase (ZA or Ctl) for both 
disease and relevant safety endpoints (16). Patient samples to be used in this study 
were selected based on: 1.) menopausal status (post-menopausal women (n=164); 
non-postmenopausal women (n=226); unknown menopausal status (n=2)), 2.) whether 
or not the patient had recurrence of breast cancer (disease-free or recurrence in bone 
only or bone as well as other distant sites), and 3.) whether or not the patient received 
adjuvant ZA treatment. These three parameters were used to power the sample size 
estimation using the reported HR of 0.81, and a standardized effect size of 0.80 (16). 
Plasma G-CSF levels were analyzed by ELISA. 
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Statistics. All experiments were performed with three independent replications, unless 
otherwise indicated. Sample size for in vivo experiment was based on outcomes from 
pilot experiments and was calculated at a statistical significance level of 0.05, and 
powered at 0.80.  All data were analyzed with the use of GraphPad Prism Software 
(Version 7). Data are expressed as mean ± SEM with n denoting the number of 
independent data points (i.e., mice, cell wells, etc.). Statistics were determined using the 
unpaired, two-tailed student’s t-test unless otherwise indicated. Results were 
considered statistically significant if p<0.05 (*), p<0.01 (**), p<0.001 (***). 
 
ELISAs and cytokine array. Plasma was obtained from the mice as previously 
described, and ELISA assays were performed according to manufacturer instructions: 
Murine G-CSF ELISA Kit (R&D Systems, MCS00); Murine OPG ELISA Kit (Raybiotech 
Inc., 501044763); Murine RANKL ELISA Kit (Innovative Research, IRKTAH5466); 
Murine NTX ELISA (Biotang Inc., 50154363). For the human cytokine array, 100,000 
cells of B1 or B2 were plated and conditioned media from 5 different wells was obtained 
24 hours after plating, was pooled and then assessed using Human Cytokine Array, 
Panel A per manufacturer’s instructions (R&D, ARY005). For the patient plasma 
samples, 100 µL of sample was used and ELISA assays were performed according to 
manufacturer instructions (Human G-CSF QKIT HS ELISA; R&D Systems, HSTCS0). 
Plates were analyzed using Softmax Pro7 Software (Molecular Devices). 
 
DATA AND SOFTWARE AVAILABILITY. RNA-Sequencing data will be available using 
the Gene Expression Omnibus (GEO; GSE108250) database. 
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RESULTS 
Identification of therapeutically induced tumor-inhibitory hematopoietic bone 
marrow cells  
We and others have reported that primary cancers, physiological aging, and drug 
treatments all affect bone marrow hematopoietic cells in ways that influence disease 
progression (8-10, 15, 17). To understand if therapeutic modulation of the bone marrow 
microenvironment would provide an effective approach for treating breast cancer bone 
metastasis, we used the nitrogen-containing bisphosphonate, zoledronic acid (ZA) in 
both immunocompromised and immunocompetent pre-clinical models of breast cancer.  
 We treated tumor-free cohorts of C57BL/6 and nude mice with a single dose of 
either ZA or vehicle control and harvested their bone marrow 5 days (C57BL/6 mice) or 
3 days (nude mice) following treatment. These are time points at which osteoclast 
activity is inhibited by ZA (15). We then used our well-established hematopoietic cell 
functional assay (15-18) to test the bone marrow for effects on growth of a bone-
metastatic human breast tumor cell line, MDA-MB-231-B1 (B1), (Figure 1A). This assay 
is designed to test any effects on tumor growth that are exclusively mediated by bone 
marrow hematopoietic cells and is based on the notion that the outgrowth of DTCs 
would be affected by any ZA-induced changes to hematopoietic cells. Importantly, 
mature osteoclasts are of hematopoietic origin but localize to the endosteal niche upon 
maturation (19). TRAP staining of the bone marrow plugs confirmed that osteoclasts 
were absent from the bone marrow samples used in these experiments (Supplemental 
Figure S1A).  
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Whole bone marrow (WBM) from both strains of control (Ctl)-treated donor mice 
had no significant effect on subcutaneous B1 tumor growth when compared with B1 
tumor cells injected alone – in these cohorts, tumors formed with ~80% incidence in 
both strains of mice (Figure 1B, Supplemental Figure S1B). However, WBM from both 
strains of ZA-treated mice significantly reduced B1 tumor incidence to <30% (Figure 1B, 
Supplemental Figure S1B), indicating that tumor suppression occurred independently of 
a functional adaptive immune system. 
To begin to understand if tumor-suppressive function is enriched in a particular 
subpopulation of hematopoietic cells, we sorted the marrow from Ctl or ZA treated mice 
into lineage-negative (Lin-) progenitor populations and mature lineage-positive (Lin+) 
populations and assessed B1 tumor growth using the bone marrow functional assay. As 
before, WBM from the ZA-treated mice suppressed B1 tumor formation; tumor 
incidence was only 50% of that from the respective Ctl cohort (Figure 1C). The Lin+ 
subpopulation from ZA-treated mice had no effect on tumor incidence, which was 
equivalent to that of the respective Ctl subpopulation (Figure 1C). In striking contrast, 
Lin- cells from ZA-treated donors significantly reduced B1 tumor incidence to only 
14.3% relative to Lin- cells from the Ctl mice (Figure 1C). 
Osteoclasts differentiate from Lin- myeloid-committed cells in the marrow (19-
21); therefore, we wondered if ZA imparted its tumor-suppressive effect via osteoclast 
precursor cells. There is currently no clear consensus on the cell-surface markers that 
delineate osteoclast precursors (21). However, given our previous report that ZA, in 
addition to inhibiting osteoclast activity, significantly expands numbers of bone marrow 
common myeloid progenitor populations (15), we reasoned that an effort to capture 
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functional activity should include multi-potent progenitors of the myeloid/osteoclast 
lineage. We therefore utilized the markers CD3-B220-Ly6G-Ly6C-CD11b-Ter119-CD115+ 
to define a population we termed ‘myeloid/osteoclast progenitors’ (M/OCPs; 
Supplemental Figure S1C). We confirmed that this sorted population from Ctl-treated 
donors gives rise to macrophages, dendritic cells, and osteoclasts in a standard in vitro 
differentiation assay (20) (Supplemental Figure S1D, S1E). 
We treated tumor-free C57BL/6 mice with a single dose of ZA and quantified the 
numbers of CD3-B220-Ly6G-Ly6C-CD11b-Ter119-CD115+ M/OCPs in the marrow over 
an experimental time course of 15 days. ZA treatment significantly increased the 
number of bone marrow M/OCPs in a time-dependent manner (Figure 1D).  
We then investigated M/OCP tumor-suppressive function by sorting CD3-B220-
Ly6G-Ly6C-CD11b-Ter119-CD115+ M/OCPs, as well as the M/OCP-depleted population, 
from the marrow of Ctl or ZA-treated cohorts and subjecting them to the bone marrow 
functional assay. As a control, we confirmed that WBM from the ZA-treated cohort 
significantly suppressed tumor growth as expected (Figure 1E, Supplemental Figure 
S1F). M/OCPs isolated 5 days after ZA-treatment significantly inhibited tumor incidence 
and mass relative to the same number of M/OCPs from the Ctl-treated cohort (Figure 
1E, Supplemental Figure S1F). In contrast, the M/OCP-depleted marrows from Ctl and 
ZA-treated mice were not significantly different in their tumor-modulating capacity 
(Figure 1E).!!
The results from the in vivo BMC functional assays suggested that M/OCPs from 
ZA-treated mice are qualitatively different than their control counterparts. Hence, we 
performed RNA sequencing on M/OCPs from Ctl and ZA-treated cohorts. 
Research. 
on September 7, 2018. © 2018 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on July 31, 2018; DOI: 10.1158/0008-5472.CAN-18-0548 
14 
 
Computational analyses revealed a list of significantly differentially expressed genes 
(DEGs) (GEO, GSE108250; Supplemental Table S1). Functionally enriched gene 
ontology (GO) terms and gene set enrichment analyses (GSEA) among the DEGs 
revealed biological and cellular processes that were enriched in the ZA-treated 
M/OCPs. Of these, “organic cyclic compound metabolic process”, “cellular aromatic 
compound metabolic process”, “oxidative phosphorylation”, “phagosome”, “lysosome 
organization”, and “lipid transport” pathways (Figure 1F, Supplemental Table S2A, S2B) 
were particularly interesting, as these processes are important for monocyte 
differentiation and macrophage function (22, 23).  
Collectively, these results established that M/OCP transcriptional programs are 
altered in the marrow and correlate with tumor-suppressive function in response to the 
bone-targeting agent, ZA, independently of a functional adaptive immune system. 
Moreover, these results are in agreement with pre-clinical findings that ZA reduces the 
risk of breast cancer recurrence independently of its direct action on osteoclast 
apoptosis (24) and that bone tumor burden can be modulated in an osteoclast-
independent manner (25). 
 
ZA skews lineage potential of myeloid/osteoclast progenitor cells toward 
macrophages  
Our RNAseq analyses suggested that M/OCPs are enriched for transcriptional 
programs consistent with those of the monocyte/macrophage lineage in response to ZA.  
Although it is well known that ZA inhibits mature osteoclasts, whether ZA affects 
myeloid/osteoclast lineage bias is not understood; therefore, we tested the lineage 
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potential of bone marrow samples from control and ZA-treated mice using in vitro 
differentiation assays (20) (Figure 2A). In these assays, macrophage-colony stimulating 
factor (M-CSF; CSF1) is necessary for sustaining M/OCP populations (26) and in the 
absence of receptor activator of nuclear factor kappa-B ligand (RANKL), these 
progenitors normally differentiate into macrophages and dendritic cells (DCs) whereas 
in the presence of RANKL, they differentiate into osteoclasts (27). 
Interestingly, when WBM samples from ZA- and Ctl-treated mice were subjected 
to M-CSF and RANKL in vitro, the marrow cells from ZA-treated donors gave rise to 
significantly fewer numbers of osteoclasts as compared to those of Ctl-treated donors 
(Figure 2B), despite having more M/OCPs (Figure 1D). Instead, the resulting cultures 
from the ZA-treated cohort had significantly increased numbers of macrophages 
(Cd11b+/F4/80+/MHCII+) and DCs (Cd11b+/MHCII+/Cd11c+) as compared to those of the 
Ctl-treated cohort (Figure 2C; Supplemental Figure S2A, S2B). In fact, these numbers 
of macrophages and DCs were comparable to those of bone marrow samples treated 
only with M-CSF (Figure 2C). !
We next tested the lineage potential of M/OCPs isolated from ZA-treated 
animals. Thus, we sorted M/OCP populations from the marrow of mice treated with Ctl 
or ZA and subjected them to the differentiation assay. In the presence of RANKL, 
M/OCPs from ZA-treated mice gave rise to significantly more macrophages than those 
of controls and these numbers were comparable to those from cultures that had not 
been treated with RANKL (Figure 2D). Although DCs were detected in the resulting 
cultures, there were no significant differences in their numbers between ZA and Ctl 
treated mice (Figure 2D, Supplemental Figure S2B). 
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Collectively, these findings indicated that ZA inherently changes the lineage 
potential of M/OCPs by skewing their differentiation potential toward macrophages, 
even in the presence of RANKL. Moreover, the marrow of ZA-treated cohorts harbor 
significantly more of these differently poised M/OCPs than that of the control 
counterparts.  
 
ZA inhibits breast cancer metastasis in a manner that is counteracted by G-CSF 
The ability to therapeutically generate tumor-suppressive bone marrow has important 
implications for bone metastasis; therefore, we tested whether pre-treating nude mice 
with ZA three days prior to intracardiac injection of breast tumor cells would affect 
subsequent bone metastasis (Figure 3A). We used two derivative bone-tropic 
subpopulations, B1 (28) and B2 (29), of the parental MDA-MB-231 breast cancer cell 
line.  
Interestingly, while B1 bone metastatic burden was significantly lower following 
ZA pre-treatment (63.7% lower than the control cohort, p<0.05), B2 metastatic burden 
was unaffected (Figure 3B-C; Supplemental Figure S3A). Likewise, ZA pre-treatment 
decreased outgrowth of B1, but not B2, bone tumors when cells were directly injected 
into the tibia (Supplemental Figure S3B). Moreover, WBM from ZA-treated mice did not 
suppress B2-derived tumor growth in the BM functional assay (Supplemental Figure 
S3C), indicating that the B2 cell line is resistant to the tumor-suppressive effect of ZA-
treated bone marrow. 
Comparative cytokine analysis revealed that the ZA-resistant B2 cell line 
expressed higher levels of G-CSF, GM-CSF, CXCL1 and IL-18 than the ZA-responsive 
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B1 cell line (Supplemental Figure S3D). Various tumor-derived factors have been 
previously shown to induce osteoclastogenesis and osteoclast activity, including cell 
surface ligand Jagged1 and secreted factors RANKL, G-CSF, GM-CSF, MIP-1α, 
PTHrP, IL-8, IL-6, ICAM1 (30, 31). In particular, elevated plasma levels of G-CSF have 
been correlated with poor prognosis for patients with triple-negative breast cancer (32) 
and enhanced osteoclast activity has been reported in mice with elevated G-CSF levels 
(33-35). Although it is well established that G-CSF leads to increased numbers of 
myeloid cells in the bone marrow (35), whether G-CSF directly affects 
osteoclastogenesis or response to ZA is not well understood. 
           To assess whether G-CSF plays a role in resistance to ZA treatment that we had 
observed, we overexpressed G-CSF in the B1 cell line, which has endogenously low G-
CSF expression, to generate a G-CSF-high cell line (B1-G) (Supplemental Figure S3E). 
Unlike the B1 bone metastases that were significantly reduced following ZA pre-
treatment (~3-fold reduction; p<0.05), the B1-G metastatic burden was no different from 
that of the control cohort and significantly higher than that of B1 cells treated with ZA 
(Figure 3B-C). ZA also failed to suppress B1 metastases when G-CSF was 
administered systemically (Supplemental Figure S3F), even though the systemic 
efficacy of G-CSF was confirmed by an expected increase in peripheral neutrophil 
counts (Supplemental Figure S3G). Of note, neutrophil numbers in the bone marrow of 
B1 tumor-bearing mice was unchanged after ZA, G-CSF, or ZA+G-CSF administration 
(Supplemental Figure S3H) and G-CSF did not alter osteoclast activity relative to Ctl-
treatment, as measured by plasma NTX (Supplemental Figure S3I).  
Research. 
on September 7, 2018. © 2018 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on July 31, 2018; DOI: 10.1158/0008-5472.CAN-18-0548 
18 
 
           To determine if G-CSF suppression is sufficient to confer ZA-response, we used 
two different shRNA constructs to suppress G-CSF in the B2 cell line, which has 
endogenously high G-CSF expression, to generate G-CSF-low cell lines (B2-shG1 and 
B2-shG2; Supplemental Figure S3E). At this time point, metastatic burden was not 
significantly affected following ZA pre-treatment regardless of G-CSF status in the B2 
cells (Figure 3B-C, Supplemental Figure S3J). Likewise, neutralizing G-CSF in vivo prior 
to IC injection of the B2 cell line did not significantly reduce metastases following ZA 
pre-treatment (Figure 3D). 
Together, these findings demonstrated that elevating G-CSF levels is sufficient to 
confer ZA resistance, but that suppression of G-CSF is not sufficient to induce ZA 
response. Moreover, these data indicated that G-CSF alone does not necessarily 
enhance metastatic burden above that of controls, but suggested that in the context of 
ZA treatment, G-CSF increases metastatic burden.  
 
G-CSF prevents generation of tumor-suppressive M/OCPs  
We next wondered if resistance to ZA under G-CSF-high conditions was due to 
counteracting effects of G-CSF on bone marrow hematopoietic cells. We started by 
analyzing the function of WBM harvested from C57BL/6 mice 5 days following 
administration of ZA, G-CSF, combination ZA+G-CSF, or vehicle control (Figure 4A). 
As we observed repeatedly, WBM from ZA-treated mice inhibited B1 tumor 
formation in vivo (Figure 4B, Supplemental Figure S4A). We also confirmed that, as 
expected, ZA decreased osteoclast activity in these mice (Supplemental Figure S4B). 
While WBM from mice treated systemically with G-CSF did not significantly alter tumor 
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growth relative to that of the control cohort, when mice were treated systemically with 
combination ZA+G-CSF, their WBM was no longer tumor suppressive (Figure 4B, 
Supplemental Figure S4A). Importantly, both WBM and M/OCPs harvested from ZA-
treated mice, which inhibited outgrowth of B1 tumor cells, were unable to inhibit growth 
of B1 tumor cells that overexpressed G-CSF (B1-G) (Figure 4C, Supplemental Figure 
S4C).  
In concordance with our findings from the in vitro differentiation assays (Figure 
2C-D), ZA significantly increased the numbers of macrophages in the marrow relative to 
vehicle control in vivo (Figure 4D). In contrast, WBM from mice treated systemically with 
G-CSF or with ZA+G-CSF contained similar numbers of macrophages as those of the 
Ctl cohort (Figure 4D).  
These results suggested that G-CSF itself does not generate a marrow 
environment that enhances tumor growth relative to the control cohorts. Instead, G-CSF 
appeared to render ZA ineffective to generate tumor-suppressive marrow.  
 
G-CSF counteracts ZA’s ability to push differentiation of myeloid/osteoclast 
progenitors toward phagocytic macrophages 
Our results thus far established that ZA alters the lineage potential of M/OCPs and 
renders them tumor-suppressive, while G-CSF mediates resistance to their tumor-
suppressive effect. We therefore wished to know if G-CSF alters the lineage potential of 
the M/OCP population.  
We first isolated WBM from Ctl-, ZA-, G-CSF, and ZA+G-CSF-treated mice and 
then treated the cells in vitro with M-CSF and RANKL (Figure 5A). As we repeatedly 
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observed, in the absence of G-CSF, WBM from the ZA-treated cohort gave rise to 
significantly fewer osteoclasts than those from the control cohorts (Figure 5B). However, 
WBM from G-CSF-treated animals gave rise to significantly more osteoclasts, even in 
the context of ZA treatment (Figure 5B).  
We also isolated M/OCPs from Ctl- or ZA- treated mice and then treated the cells 
in vitro with M-CSF and RANKL in the presence or absence of G-CSF (Figure 5C). In 
the presence of G-CSF, M/OCPs from both Ctl- and ZA-treated mice gave rise to 
increased numbers of osteoclasts and decreased numbers of macrophages in vitro 
relative to M/OCPs in the absence of G-CSF (Figure 5D, 5E, Supplemental Figure S5A, 
S5B). 
Our RNAseq analyses of M/OCPs from Ctl and ZA-treated mice (Fig. 1F) had 
suggested that ZA induces transcriptional changes consistent with 
monocyte/macrophage lineage bias. Therefore, to test potential functional 
consequences of altered M/OCP lineage potential, we added fluorescently labeled B1 
tumor cells to the cultures resulting from M/OCP differentiation under various conditions, 
thus enabling us to assess macrophage phagocytic capacity by scoring their uptake of 
fluorescence. In the absence of G-CSF, macrophages derived from M/OCPs of ZA-
treated mice had significantly enhanced phagocytic capacity relative to those from Ctl-
treated mice, irrespective of adding RANKL to the culture (Figure 5F). In contrast, G-
CSF significantly decreased the phagocytic capacity of the resulting culture from ZA-
treated M/OCPs in both the undifferentiated (without RANKL) and differentiated (with 
RANKL) cultures (Figure 5F). Consistent with the phagocytic phenotype, numbers of 
F4/80 MHCII+ macrophages in the bone marrow of ZA-treated mice was ~3-fold higher 
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than in the control cohort, and G-CSF prevented this increase (Supplemental Figure 
S5C).   
Collectively, these findings suggested that G-CSF counteracts the effect of ZA on 
M/OCP function and lineage potential at least in part by preventing ZA from inducing 
M/OCP differentiation toward phagocytic macrophages. Moreover, these results provide 
additional evidence to suggest an association between lineage potential and the tumor-
inhibitory function of the bone marrow. 
 
Bone marrow transcriptome and gene ontology processes that correlate with 
function 
The results from our pre-clinical metastasis models thus far indicated that the status of 
the bone marrow at the time metastatic tumor cells encounter it has a profound 
influence on metastatic success. As such, we wanted to gain insights into how the 
whole bone marrow hematopoietic microenvironment is affected by ZA and how G-CSF 
may alter the ZA signature. We therefore characterized transcriptional programs (RNA-
seq) on whole bone marrow from mice treated with Ctl, ZA, G-CSF, or combination 
ZA+G-CSF (GSE108250).  
We first analyzed the RNA-seq data by identifying enriched gene ontology 
processes (36) within the lists of DEGs from each treatment condition (ZA, G-CSF, or 
ZA+G-CSF) as compared to Ctl-treated bone marrow (Supplemental Figure S6A-C, 
Supplemental Tables S3A-F). In the ZA-treated cohort, significantly enriched processes 
were related primarily to metabolic process whereas in the G-CSF-treated cohorts, as 
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well as in the ZA+G-CSF-treated cohorts, significantly enriched processes were 
dominated by immune processes (Supplemental Figure S6C).  
 A global analysis of gene expression differences between each of the 3 
treatment cohorts (ZA, G-CSF, and ZA+G-CSF) and the control cohort (Ctl) provided 
insights into the effect of each treatment on WBM and M/OCPs. For WBM, the 
comparisons identified 56, 1,445 and 1,054 DEGs (modified BH adjusted p-value <0.01) 
in the ZA, G-CSF, and ZA+G-CSF cohorts, respectively (Figure 6A, Supplemental 
Figure S6A-B, Supplemental Table S4A-C). 779 DEGs were common to both the G-
CSF and ZA+G-CSF comparisons, only 28 of which were also shared with the ZA 
comparison (Figure 6A). The 28 DEGs that were affected by all 3 treatments were the 
only DEGs shared between the ZA and ZA+G-CSF comparisons (Figure 6A). 
Importantly, 16 DEGs were affected exclusively by ZA treatment (i.e., not identified in 
the combined treatment comparison) and included genes involved in phagocytosis such 
as Slc15a4, Usp37, and Ipo13 (Figure 6A and Supplemental Table S4A).  Interestingly, 
~25% of the DEGs resulting from combination ZA+G-CSF were unique to that treatment 
cohort (Figure 6A). 
 In the M/OCPs, 165 DEGs resulted from ZA treatment, 314 from G-CSF 
treatment, and 151 from combination ZA+G-CSF (Figure 6A, Supplemental Tables S5A, 
S5B, S5C). As observed with WBM, a number of DEGs (~38%) were unique to the 
combination treatment.  103 DEGs were affected exclusively by ZA treatment (Figure 
6A). Interestingly, Mapk8ip2 was one of the most significantly up-regulated DEGs in the 
ZA-treated cohort (p=3.39x10-14), but was down-regulated in both G-CSF-treated 
(p<8.48x10-4), and ZA+G-CSF-treated cohorts (p=4.31x10-6). Mapk8ip2 is involved in 
Research. 
on September 7, 2018. © 2018 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on July 31, 2018; DOI: 10.1158/0008-5472.CAN-18-0548 
23 
 
monocyte differentiation into macrophages when activated (37) (Supplemental Table 
S5A). 
These analyses revealed that both G-CSF and ZA significantly and uniquely 
affect transcriptional programs in the WBM and that combined treatment yields yet a 
different transcriptional profile from either treatment alone. Moreover, ZA treatment 
appeared to have a larger impact on M/OCPs than on WBM, while G-CSF appeared to 
dominate the effect on WBM.  
 
Effects of ZA that are lost or significantly changed in the presence of G-CSF   
We considered the transcriptional effects we observed with each treatment and 
the fact that ZA treatment generated metastasis-suppressive marrow while G-CSF 
alone had no effect on metastatic burden, yet G-CSF induced resistance to ZA and 
increased metastatic burden in the context of ZA treatment. In doing so, we speculated 
that ZA and G-CSF either affect the marrow in opposing directions or that the effects of 
combination treatment cannot be explained by contributions of either treatment alone.  
Our comparative analysis revealed that the DEGs upon combination treatment 
were not equivalently significant in either the ZA or G-CSF cohorts (Figure 6A). In other 
words, none of these genes was expressed in an opposing manner. Indeed, 263 DEGs 
were unique to WBM and 58 genes unique to the M/OCP population in the ZA+G-CSF 
cohorts (Figure 6A). Hence, we employed a regression approach with an interaction 
term and identified genes for which the effects of G-CSF and ZA statistically interact 
(Figure 6B, Supplemental Table S6A-B).  
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GO analysis of these non-additively differentially expressed genes from WBM 
revealed processes significantly enriched by the combination treatment that described 
the difference in response to ZA in the presence of G-CSF (Figure 6C, Supplemental 
Table S7). The enrichment list represents gene sets that were either enhanced or 
ablated relative to the cumulative effects expected from adding together the effects of 
ZA and G-CSF treatments alone, including those newly emerging with combination 
treatment. Of these, “immune response” and “phagocytosis” were particularly intriguing 
to us, as these were predominantly suppressed by combination treatment. For example, 
a number of genes involved in antigen processing and lymphocyte activation, including 
B2m, Vav2, and a number of histocompatibility genes (H2-K1, H2-D1, H2-Q5, H2-Q7) 
were uniquely suppressed with ZA+G-CSF combination treatment relative to Ctl 
treatment (Supplemental Table S6A). Moreover, Axl, which suppresses myeloid cell 
immune function and dampens NK cell activity (38), was significantly suppressed by ZA 
treatment (log2(Fold Change)= -1.20, p=1.25x10-4) but significantly enhanced with 
ZA+G-CSF treatment (log2(Fold Change)=1.68, p=2.7x10-5) (Supplemental Table S6A)  
Together with our pre-clinical modeling, these analyses indicated that in the 
marrow of animals treated with combination ZA + G-CSF, the transcriptional effects of 
ZA are negated and/or significantly changed by G-CSF in a manner that associates with 
metastatic progression. 
 
High plasma G-CSF correlates with worse outcome for breast cancer patients 
treated with adjuvant ZA 
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Our pre-clinical data established that G-CSF mediates resistance to ZA, and in fact, 
ZA+G-CSF combination treatment had unexpected effects on the metastatic 
microenvironment, resulting in enhanced metastasis relative to ZA treatment alone. 
Hence, we sought to understand if patient plasma G-CSF levels correlate with response 
to ZA.  In the clinical setting, bisphosphonates have suggested benefit, as demonstrated 
by results from a meta-analysis in which patients who had received adjuvant 
bisphosphonate treatment observed a significant reduction in breast cancer recurrence 
in the bone (39). Nevertheless, responses have been limited for unknown reasons and 
biomarkers that can be used to guide treatment decisions are lacking. 
We analyzed patient plasma samples (n=392) from the AZURE clinical trial in 
which women with stage II/III breast cancer were randomized to receive standard 
systemic treatment (>95% of the patients received chemotherapy) with or without 
adjuvant ZA (16) (Figure 7A). In the AZURE trial, postmenopausal (natural or induced 
with ovarian suppression) patients observed a significant decrease in overall breast 
cancer recurrence (16). Importantly, primary G-CSF prophylaxis was not used in these 
patients. We verified that the magnitude of effect of ZA in reducing the development of 
bone metastasis at any time during the 10-year follow-up in our patient subset was 
similar to that of the overall trial (trial total n=3,360, hazard ratio (HR)=0.81, 95% 
confidence interval (CI) 0.68-0.97 (16); our subset n=392, HR=0.89, 95% CI 0.62-1.3) 
(Figure 7A). 
We utilized an analytical approach that adjusts for an optimal plasma G-CSF 
concentration cut point and enables us to accurately determine DFS and significance 
levels in an unbiased fashion (40) (See Methods, Supplemental Figure 7A-D). Based on 
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these previously published methods, we determined that a plasma G-CSF concentration 
of 23 pg/mL was the optimum cut-point for assessing disease-free survival (DFS) 
events in ZA-treated patients (40).  
Patients receiving adjuvant ZA whose plasma G-CSF levels were > 23 pg/mL at 
the time of randomization had significantly reduced DFS when compared with patients 
with plasma G-CSF levels < 23 pg/mL (p adjusted=0.02) as assessed over a 10-year 
period (Figure 7B). However, in the cohort that did not receive ZA, plasma G-CSF levels 
did not predict a significant difference in DFS (Supplemental Figure S7B). Cox model 
analysis demonstrated that the relationship between high plasma G-CSF levels and 
DFS in ZA-treated patients could not be explained by imbalances in other key 
prognostic variables, namely number of involved lymph nodes affected, tumor size (T 
stage), and breast cancer receptor status (ER/PR/Her2). Moreover, in support of the 
retrospective analyses demonstrating that post-menopausal patients observed 
significant benefit with adjuvant ZA, plasma G-CSF levels were significantly lower in 
post-menopausal patients than pre-menopausal patients in our cohort (p=1.14x10-4). 
 
DISCUSSION  
This work revealed that bone marrow hematopoietic cell states, particularly M/OCP 
lineage potential, have a profound impact on breast cancer bone metastasis and that 
the hematopoietic microenvironment, which serves as a niche for disseminated tumor 
cells, can be modulated by bone-targeting agents and cytokines to alter disease 
outcome. Specifically, the bisphosphonate, ZA, directs M/OCP lineage potential toward 
tumor-suppressive macrophages and prevents metastatic growth in the bone; systemic 
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or tumor-derived G-CSF promotes resistance to the metastasis-suppressive effect of ZA 
by skewing M/OCP differentiation toward osteoclasts and away from the phagocytic 
myeloid lineage (Figure 7C).  
Further mechanistic investigation into the newly identified biology that we report 
here is warranted in order to understand how best to capitalize on bone marrow and 
M/OCP function and differentiation potential to prevent or limit metastatic disease in the 
bone. The novel, perhaps unexpected effect of ZA on the bone microenvironment may 
provide one such avenue. From a clinical perspective, targeting osteoclast activity with 
bone-modifying agents, such as bisphosphonates or the RANK-ligand inhibitor 
denosumab, has significantly reduced skeletal-related events patients with metastatic 
breast cancer to the bone (i.e. bone fractures, bone pain requiring radiation therapy, 
spinal cord compression, and hypercalcemia), (41). Thus, current NCCN guidelines 
support the administration of these agents in combination with chemotherapy or 
endocrine therapy for patients with bone metastases (category 1 recommendation) (42, 
43). Results from a meta-analysis of individual patient data from 18,766 women – 
enrolled over 26 randomized trials that evaluated the benefits of adjuvant 
bisphosphonate treatment – showed a significant reduction in bone recurrence and 
improvement in breast cancer specific survival (44). 
Subgroup analyses have suggested that postmenopausal status, but not 
hormone receptor (ER/PR) or growth factor receptor (Her2) expression, predisposes 
patients who are more likely to benefit from bisphosphonates, and this is reflected in the 
recently published guidelines by Cancer Care Ontario (CCO) and the American Society 
of Clinical Oncology (ASCO) that recommend consideration of zoledronic acid (ZA) or 
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clodronate for postmenopausal (natural or induced with ovarian suppression) patients 
deemed candidates for adjuvant systemic therapy (43). Other meta-analyses revealed 
that adjuvant therapy with ZA increases overall survival in early stage breast cancer 
(44). Additionally, ZA decreased the number of DTCs in the bone marrow of Stage II/III 
breast cancer patients in a randomized clinical trial (45). ZA has also been 
demonstrated to increase disease free survival when it is administered with neoadjuvant 
chemotherapy, particularly in post-menopausal patients (46). Nevertheless, an 
underlying biological explanation for the protective effect of bisphosphonates in breast 
cancer, in terms of reduction of disease recurrence, had remained elusive.   
Although meta-analyses of the clinical studies highlighted efficacy of ZA, no 
overall survival benefit has been reported to date in individual randomized controlled 
trials in breast cancer.  Consequently, even considering pre- or post-menopausal status, 
it remained unclear how to identify which patients would observe benefit with ZA (16). 
Our findings provide new insights into why certain patients may not see reduction in 
breast cancer recurrence with ZA. Our pre-clinical findings are underscored by the fact 
that patients in the AZURE trial (16) with higher plasma G-CSF levels experienced 
worse outcome from adjuvant ZA-treatment and provide preliminary evidence to caution 
against the use of ZA in patients with high plasma G-CSF. High plasma G-CSF, 
however, has been correlated with poor prognosis in breast cancer patients, specifically 
those with triple-negative breast cancer (32). However, in our study, plasma G-CSF 
levels alone, in the absence of ZA treatment, did not predict worse survival.  
Unfortunately, our findings provide a preliminary indication that suppression of G-
CSF may not be an effective strategy for improving responses to ZA, as neither genetic 
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nor pharmacological inhibition of G-CSF was sufficient to confer response. It is possible 
that the balance between tumor-promoting (8) and tumor-suppressive cells in the 
marrow, or other cytokines (such as GM-CSF) must be considered in the appropriate 
contexts. Further studies to evaluate our findings will therefore require well-designed 
pre-clinical and clinical trials to determine patient benefit with adjuvant ZA in the 
presence or absence of G-CSF administration. Our analyses suggest other ways to 
achieve this goal may be to include combinations with other bone-targeting agents or 
immunotherapies. Further studies based on results of our gene expression profiling 
under these various conditions may reveal factors, pathways, and processes that are 
necessary and/or sufficient for the tumor inhibitory function of the bone marrow. Some 
of the newly identified gene products presented here may be considered as candidate 
targets for future combination therapies and pre-clinical research. 
Likewise, additional work will be necessary to determine the translatability of G-
CSF as a biomarker for selection of patients who should/should not receive ZA 
treatment, given that many patients also receive G-CSF at the time of chemotherapy 
and adjuvant ZA treatment (the patients in our study did not receive primary G-CSF 
prophylaxis and less than 10% received secondary G-CSF treatment). Identifying 
biomarkers that better stratify patient risk and responses to ZA hold the potential of 
using bone-modulating drugs to improve patient outcomes. 
Identification of a tumor-suppressive population in the bone marrow provides 
opportunities for exploring new therapeutic strategies that could generate such cells in 
order to halt metastatic progression or overcome the adverse effects of G-CSF. The 
ability to use relatively safe bone-modulating therapeutics to capitalize on the tumor-
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suppressive function of the bone marrow, particularly M/OCP populations, provides a 
foundation for potentially curative treatments during the time when metastatic breast 
cancer can still be controlled.  
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FIGURE LEGENDS 
 
Figure 1. Identification of therapeutically induced tumor-inhibitory hematopoietic 
bone marrow cells  
(A) Experimental scheme for assay to test bone marrow cell (BMC) tumor support 
function. Whole bone marrow (WBM) or various FACS-isolated bone marrow 
populations were harvested from zoledronic acid (ZA)- or vehicle-treated control (Ctl) 
donor mice at either 5 days (C57BL/6) or 3 days (Nude) and mixed with tumor cells 
immediately prior to injection into recipient mice and tumor incidence and growth 
kinetics measured over time.   
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(B) Incidence (%) of subcutaneous tumor formation in nude recipient mice at 
experimental endpoint (d14) resulting from 2.5x105 MDA-MB-231-B1 (B1) cells admixed 
with matrigel (NA, no donor BMCs included) or 7.5x105 WBM cells from Ctl or ZA 
treated nude and C57BL/6 donors (n=4-7 injections per cohort, statistics representative 
of 2 biological replications).  
(C) Incidence (%) of subcutaneous tumor formation in nude recipient mice at 
experimental endpoint (d14) resulting from 2.5x105 MDA-MB-231-B1 (B1) cells admixed 
with 7.5x105 whole BMCs (WBM), 7.5x105 Lin+ BMCs, or 2.5x105 Lin- BMCs from Ctl or 
ZA treated nude donors. Data for each ZA-treated cohort are represented relative to its 
respective Ctl-treated cohort; (n=20-24 injections per cohort). Lin- populations were 
sorted by gating on: CD3- Ly-6G/Ly6-C- Cd11b- CD45R- and TER119- and all of the 
remaining BMCs were used as the Lin+ populations.!
(D) Number of myeloid/osteoclast progenitor cells (M/OCPs; Lin-CD115+) in bone 
marrow of C57BL/6 mice at indicated time points after ZA treatment (n=4-5 mice per 
cohort, representative of 3 biological replications).  
(E) Incidence (%) of tumor formation in nude recipient mice at experimental endpoint 
(d14) resulting from 2.5x105 B1 cells admixed with 7.5x105 WBM cells, 105 sorted 
M/OCPs, or 6.5x105 M/OCP-depleted BMCs from Ctl- or ZA-treated C57BL/6 donors 
(n=6 injections per cohort, statistics representative of 2 biological replications).  Controls 
from different cohorts are not compared due to the fact that different numbers of BMCs 
are admixed with tumor cells in each case.   
(F) GSEA analysis (clusterProfiler tool using KEGG gene sets) and gprofileR (GO) 
analysis of the differentially expressed genes in M/OCPs isolated from ZA-treated mice 
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as compared to M/OCPs isolated from Ctl-treated mice. Significance was determined as 
described in Methods: RNA-sequencing. 
Error bars represent mean ± SEM; two-tailed t-tests (unpaired) were used to determine 
statistical significance, *p<0.05, ***p<0.001.!
 
Figure 2. ZA skews lineage potential of myeloid/osteoclast progenitor cells 
toward macrophages  
(A) Experimental scheme for in vitro osteoclast (OC) differentiation assay with whole 
bone marrow (WBM) or M/OCPs from Ctl- or ZA-treated C57BL/6 donors.  
(B) Quantification of OCs (TRAP+, multinucleated cells) at endpoint of in vitro OC 
differentiation assay (d5) with WBM from Ctl- or ZA-treated C57BL/6 donors (n=5 donor 
samples/cohort; representative of 3 biological replications).  
(C-D) Flow cytometric quantification of macrophages (Mφs); Cd11b+/F4/80+/MHCII+) 
and dendritic cells (DCs; Cd11b+/MHCII+/Cd11c+) from sorted WBM populations (C) 
(n=5 donor samples/cohort; representative of 3 biological replications) or M/OCPs (D) 
(n=6-7 donor samples/cohort; representative of 3 biological replications) from Ctl- or ZA-
treated C57BL/6 donors at endpoint (d5) of OC differentiation assay. Error bars 
represent mean ± SEM; two-tailed t-tests (unpaired) were used to determine statistical 
significance, *p<0.05. 
 
Figure 3. ZA inhibits breast cancer metastasis in a manner that is counteracted by 
G-CSF  
(A) Experimental scheme for intracardiac (IC) injections of indicated breast tumor cells 
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into Ctl or ZA pre-treated nude mice.  
(B) Total tumor burden at experimental end point as quantified by bioluminescence 
imaging (n=4-9/cohort); representative of 3 biological repetitions.  
(C) Representative bioluminescence images from indicated cohorts in (B) at 
experimental end point.  
(D) Experimental scheme for IC injections of B2 cell line following pre-treatment with Ctl 
or ZA and a G-CSF neutralizing antibody or isotype-matched control antibody (IMC) 
(top). Graph represents total tumor burden at experimental end point (d10) as quantified 
by bioluminescence imaging of the luciferase+ B2 cell line. All mice had signal present. 
(d10) (n=4-5/cohort). 
Throughout, error bars represent mean ± SEM; two-tailed t-tests (unpaired) were used 
to determine statistical significance, *p<0.05. 
 
Figure 4. G-CSF prevents generation of tumor-suppressive M/OCPs  
(A) Experimental scheme for assay to test tumor support function of BMCs from 
indicated donor mice.  
(B) Incidence (%) of subcutaneous tumor formation in nude recipient mice at 
experimental end point (d14) resulting from B1 cells admixed with WBM from Ctl-, ZA-, 
G-CSF (G)-, or ZA+G-CSF (ZA+G)-treated C57BL/6 donors (n=4-6 tumors per cohort, 
statistics representative of 2 biological replications).  
(C) Incidence (%) of tumor formation in nude recipient mice at experimental end point 
(d14) resulting from B1 or B1-G cells admixed with WBM or sorted M/OCPs from Ctl- or 
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ZA- treated C57BL/6 donors (n=4-6 tumors per cohort, statistics representative of 2 
biological replications).  
(D) Quantitative flow cytometric analysis of WBM from indicated mice for number of 
macrophages (Cd11b+/F4/80+/MHCII+) 3 days after Ctl (C), ZA (Z), G-CSF (G), or G-
CSF+ZA (G+Z) treatment (n=4-5/cohort; representative of 3 biological replications). 
Throughout, error bars represent mean ± SEM; two-tailed t-tests (unpaired) were used 
to determine statistical significance, *p<0.05. 
 
Figure 5. G-CSF counteracts ZA’s ability to push differentiation of 
myeloid/osteoclast progenitors toward phagocytic macrophages  
(A) Experimental scheme for in vitro osteoclast differentiation assay using bone marrow 
from Ctl-, ZA-, G-CSF- or ZA+G-CSF-treated C57BL/6 donors  
(B) Quantification of osteoclasts (OC, TRAP+, multinucleated cells) at endpoint (d5) of 
in vitro osteoclast differentiation assay with 1,000 WBM per well Ctl, ZA, G-CSF or 
ZA+G-CSF treated C57BL/6 donors (n=4 donor samples/cohort; representative of 3 
biological replications).  
(C) Experimental scheme for in vitro osteoclast differentiation assay using bone marrow 
from Ctl- or ZA-treated C57BL/6 donors that were subsequently treated with Ctl or 
recombinant hG-CSF in vitro at d3  
(D) Quantification of osteoclasts (OC, TRAP+, multinucleated cells) at endpoint (d5) of 
in vitro osteoclast differentiation assay with 250 M/OCPs per well from Ctl or ZA treated 
C57BL/6 donor mice; M/OCPs were treated in vitro with RANKL ± G-CSF (n=4 donor 
samples per cohort; representative of 3 biological replications).  
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(E) Flow cytometric quantification of macrophages (Cd11b+/F4/80 MHCII+) at end point 
of in vitro OC differentiation assay (d5) using sorted M/OCPs from Ctl or ZA treated 
C57BL/6 mice; M/OCPs were subsequently treated in vitro with M-CSF and RANKL ± 
G-CSF (n=4 donor samples per cohort; representative of 3 biological replications).  
(F) Percent of phycoerythrin (PE)-positive M/OCP-derived macrophages (Cd11b+ 
F4/80+ MHCII+) at end point (d5), indicating phagocytosis of Did-Cm (PE)-labeled B1 
tumor cells (n=4 donor samples per cohort, representative of 3 biological replications). 
Error bars represent mean ± SEM; two-tailed t-tests (unpaired) were used to determine 
statistical significance, *p<0.05, **p<0.01. 
 
Figure 6. Bone marrow transcriptome and gene ontology processes that correlate 
with function 
 (A) Venn-Diagrams for distinct and non-distinct differentially expressed genes in the 
bone marrow (left) or M/OCPs (right) from mice treated with ZA (blue), G-CSF (red) or 
ZA+G-CSF (“Both”, yellow), as normalized to Ctl-treated bone marrow or M/OCPs 
(modified BH adjusted p-value less than 0.01).  
(B) Heatmap of expression levels of genes identified from a regression analysis of the 
interaction between G-CSF and ZA effects on gene expression for whole bone marrow 
(left) or M/OCPs (right). Individual sample expression levels are shown for genes with a 
modified BH adjusted p-value of less than 0.01 from the regression. Values represent 
normalized counts after centering on the mean expression levels of the control samples 
and scaling to the range of gene expression across all samples (so that -1 represents 
the lowest expression level for all samples and 1 the highest).  
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(C) Enriched gene ontology categories for genes for which the simultaneous effects of 
G-CSF and ZA treatment on expression were not additive in a comparative analysis 
model for whole bone marrow. Categories for each indicated cohort were compared to 
control using the non-additive genes (as ordered by absolute log2 fold change; modified 
BH adjusted p-value less than 0.01 A list of the statistically enriched gene ontology 
(GO) terms for biological processes was generated using the methods described in (A)).  
 
Figure 7. High plasma G-CSF correlates with worse outcome for breast cancer 
patients treated with adjuvant ZA  
(A) AZURE clinical trial randomization scheme from Coleman et al., 2014  (16) and Cox 
proportional hazards model analysis of subgroup from AZURE trial (n=392) for DFS by 
Ctl and ZA cohorts, menopausal status, and by menopausal status for treatment group; 
*p<0.05. 
(B) Disease-free survival (DFS) outcome (derived from cut point analysis—see STAR 
methods) defined in terms of number of DFS events avoided/saved over the 10-year 
period post randomization among ZA-treated patients; optimal cut point was at 23 
pg/mL G-CSF. 
(C) Proposed model. ZA inhibits mature osteoclasts and also increases the numbers of 
M/OCPs in the BM, altering their gene expression profile to drive them toward tumor 
suppressive phagocytic macrophages. Tumor-derived or systemic G-CSF counteracts 
the effects of ZA by driving the lineage potential of M/OCPs toward osteoclasts.  
 
 
Research. 
on September 7, 2018. © 2018 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on July 31, 2018; DOI: 10.1158/0008-5472.CAN-18-0548 
Research. 
on September 7, 2018. © 2018 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on July 31, 2018; DOI: 10.1158/0008-5472.CAN-18-0548 
Research. 
on September 7, 2018. © 2018 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on July 31, 2018; DOI: 10.1158/0008-5472.CAN-18-0548 
Research. 
on September 7, 2018. © 2018 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on July 31, 2018; DOI: 10.1158/0008-5472.CAN-18-0548 
Research. 
on September 7, 2018. © 2018 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on July 31, 2018; DOI: 10.1158/0008-5472.CAN-18-0548 
Research. 
on September 7, 2018. © 2018 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on July 31, 2018; DOI: 10.1158/0008-5472.CAN-18-0548 
Research. 
on September 7, 2018. © 2018 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on July 31, 2018; DOI: 10.1158/0008-5472.CAN-18-0548 
Research. 
on September 7, 2018. © 2018 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on July 31, 2018; DOI: 10.1158/0008-5472.CAN-18-0548 
 Published OnlineFirst July 31, 2018.Cancer Res 
  
Jessalyn M. Ubellacker, Ninib Baryawno, Nicolas Severe, et al. 
  
prevent bone metastasis in breast cancer
Modulating bone marrow hematopoietic lineage potential to
  
Updated version
  
 10.1158/0008-5472.CAN-18-0548doi:
Access the most recent version of this article at:
  
Material
Supplementary
  
 http://cancerres.aacrjournals.org/content/suppl/2018/07/31/0008-5472.CAN-18-0548.DC1
Access the most recent supplemental material at:
  
Manuscript
Author
edited. 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been
  
  
  
  
  
  
  
E-mail alerts  related to this article or journal.Sign up to receive free email-alerts
  
Subscriptions
Reprints and 
  
.pubs@aacr.orgDepartment at
To order reprints of this article or to subscribe to the journal, contact the AACR Publications
  
Permissions
  
Rightslink site. 
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC)
.http://cancerres.aacrjournals.org/content/early/2018/07/31/0008-5472.CAN-18-0548
To request permission to re-use all or part of this article, use this link
Research. 
on September 7, 2018. © 2018 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on July 31, 2018; DOI: 10.1158/0008-5472.CAN-18-0548 
